Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102151 · ClinicalTrials.gov registry record
Reducing the Duration of Untreated Psychosis
A clinical trial, sponsored by University of Southern California.
- Completed
- Registry status
- 137
- Enrollment target
NCT03102151: Completed study, sponsored by University of Southern California.
NCT03102151 is a clinical trial that has completed, run by University of Southern California. The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03102151 has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
Study Summary
The study examines the possible effect of a community campaign to decrease the duration of untreated psychosis in persons with their first episode of a psychotic disorder.
Primary Outcome
The time from the onset of psychosis to the time the subject receives appropriate mental health treatment. The metric is number of weeks that the person went without treatment from illness onset. The number of weeks is the variable of interest that will be aggregated.
Interventions
- OTHER Community Campaign La CLAVE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2014-05 |
| Est. Completion | 2019-08-30 |
What the finished NCT03102151 record still lists
NCT03102151 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Community Campaign La CLAVE is the first listed.
NCT03102151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03102151 about?
NCT03102151 is a clinical study titled "Reducing the Duration of Untreated Psychosis". The study examines the possible effect of a community campaign to decrease the duration of untreated psychosis in persons with their first episode of a psychotic disorder.
What is the current status of trial NCT03102151?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2014-05. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03102151?
The interventions under investigation include: Community Campaign La CLAVE (OTHER).
Who is sponsoring clinical trial NCT03102151?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia